Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
tHPvrtdES7Mngbkd
